Back to results
US 2013/0095476 A1Published application
Detection of quantitative genetic differences
AssigneeZoragen Biotechnologies LLP
InventorAlexandre Loktionov
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeZoragen Biotechnologies LLP
InventorAlexandre Loktionov
Estimating the term…
A method for detection of a quantitative difference between the amount of a first target region of nucleic acid and a second target region of nucleic acid in a sample, comprising the steps of: providing the sample comprising the nucleic acid; amplifying the first and second target regions of the nucleic acid to obtain multiple copies of a first and a second sequence of nucleic acid; associating the amplified first sequence with the amplified second sequence to form associated nucleic acid complexes which comprise the first sequence and the second sequence in a 1:1 ratio, wherein any excess of either the first sequence or the second sequence remain un-associated; detecting any un-associated sequences, wherein detection of any un-associated sequences is indicative of a quantitative difference between the amount of the first and second target regions of nucleic acid in the sample.
A method for detection of a quantitative difference between the amount of a first target region of nucleic acid and a second target region of nucleic acid in a sample, comprising the steps of:
A method for detection of an abnormality in a gene or chromosome copy number in a sample, comprising the steps of:
The method according to any preceding claim further comprising the step of eliminating the associated nucleic acid complexes before detecting any un-associated sequences.
The method according to any preceding claim, wherein detecting any un-associated sequences comprises amplifying any un-associated sequences and detecting any amplification product.
The method according to any preceding claim, wherein the nucleic acid is a mixture of nucleic acid from malignant and normal/non-malignant tissue.
The method according to any preceding claim, wherein the first sequence comprises the sequence of the first target region, or complement thereof, and an additional sequence provided by a primer and/or the second sequence comprises the sequence of the second target region or complement thereof, and an additional sequence provided by a primer.
The method according to any preceding claim, wherein the first sequence of nucleic acid is amplified from the nucleic acid using a first primer pair and the second sequence of nucleic acid is amplified from the nucleic acid using a second primer pair.
The method according to any preceding claim, wherein the sense strands of the first sequence and second sequence are associated and the anti-sense strands of the first and second sequences are removed prior to the association step.
The method according to any preceding claim, wherein the step of associating the first sequence with the second sequence to form the associated nucleic acid complex comprises ligating the first sequence to the second sequence.
The method of any preceding claim which comprises amplifying more than one first target sequence and/or more than one target second sequence.
The method according to any preceding claim, wherein the first target region is a part of a gene, operon, or chromosome which is associated with an abnormality, a disease, disability or other clinical syndrome and the second target region is part of a gene, operon, or chromosome which is used as a control/standard, which is known to be present in normal copy number, or vice versa.
Use of the method according to any preceding claim to determine if an individual has an increase or decrease in gene or chromosome copy number.
Use of the method according to any preceding claim to determine the choice of treatment for a condition, optionally, wherein the condition is cancer;
Dependencies are inferred from the claim text.